Archive \ Volume.15 2024 Issue 1

A Randomized Clinical Trial on Topical Ketorolac Administration Following Phaco-Surgery for Pseudoexfoliation Syndrome

Mitra Akbari*✉ , Reza Soltani Moghadam , Anvar Mohamadpour , Ehsan Kazemnezhad Leili , Ebrahim Azaripour
  1. Eye Research Center, Department of Eye, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Science, Rasht, Iran.

Abstract

The current randomized clinical trial was conducted to determine the influence of topical ketorolac combination with steroids on anterior segment inflammation and other adverse effects following phaco-surgery for pseudoexfoliation (PEX) syndrome. A total of eighty-eight patients with PEX and cataracts who had undergone phacoemulsification participated in the trial. They were randomly placed into one of two groups, which received betamethasone (0.1%) and chloramphenicol (5%) for two weeks, either with or without ketorolac eye drops (0.5%). The two groups' six-month post-operative differences in ACO (Anterior Capsule Opacification) and PCO (Posterior Capsule Opacification) were compared using SPSS 21 software. Measurements of BCVA (Best-Corrected Visual Acuity), IOP (Intraocular Pressure), and ACI (Anterior Chamber Inflammation) were taken on days 1, 3, 7, and 30 after surgery.

Between the 46 patients in the study group (who took ketorolac) and the 42 patients in the control group (who did not take ketorolac), there was no change in IOP or BCVA on days 30, 7, 3, and 1 following surgery (P > 0.05). The study group had reduced levels of PCO and ACO at six months postoperatively (P <0.05), as well as decreased ACI on days 30, 7, and 3 postoperatively (P <0.05). After cataract surgery, individuals with cataracts and PEX saw a synergistic effect on post-operative ACI reduction when ketorolac eye drops were combined with steroid eye drops. This combination also had further impacts on PCO and ACO reduction.


Downloads: 197
Views: 964

How to cite:
Vancouver
Akbari M, Soltani Moghadam R, Mohamadpour A, Leili EK, Azaripour E. A Randomized Clinical Trial on Topical Ketorolac Administration Following Phaco-Surgery for Pseudoexfoliation Syndrome. Arch Pharm Pract. 2024;15(1):40-6. https://doi.org/10.51847/cvqPvgruf5
APA
Akbari, M., Soltani Moghadam, R., Mohamadpour, A., Leili, E. K., & Azaripour, E. (2024). A Randomized Clinical Trial on Topical Ketorolac Administration Following Phaco-Surgery for Pseudoexfoliation Syndrome. Archives of Pharmacy Practice, 15(1), 40-46. https://doi.org/10.51847/cvqPvgruf5

Download Citation
References
  1. Cagini C, Cerquaglia A, Pellegrino A, Iannone A, Lupidi M, Fiore T. Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects. Acta Ophthalmol. 2021;99(1):e70-3.
  2. Ilveskoski L, Taipale C, Tuuminen R. Anti-inflammatory medication of cataract surgery in pseudoexfoliation syndrome - NSAID is needed. Curr Eye Res. 2020;45(7):814-9.
  3. Wu Q, Li Y, Wu L, Wang CY. Hydrophobic versus hydrophilic acrylic intraocular lens on posterior capsule opacification: A Meta-analysis. Int J Ophthalmol. 2022;15(6):997-1004. 
  4. Horn JD, Fisher BL, Terveen D, Fevrier H, Merchea M, Gu X. Academy IRIS® registry analysis of incidence of laser capsulotomy due to posterior capsule opacification after intraocular lens implantation. Clin Ophthalmol. 2022;16:1721-30.
  5. Kwon YR, Hwang YN, Kim SM. Posterior capsule opacification after cataract surgery via implantation with hydrophobic acrylic lens compared with silicone intraocular lens: A systematic review and meta-analysis. J Ophthalmol. 2022;2022:3570399. 
  6. Mylona I, Tsinopoulos I. A critical appraisal of new developments in intraocular lens modifications and drug delivery systems for the prevention of cataract surgery complications. Pharmaceuticals (Basel). 2020;13(12):448. 
  7. Topete A, Tang J, Ding X, Filipe HP, Saraiva JA, Serro AP, et al. Dual drug delivery from hydrophobic and hydrophilic intraocular lenses: In-vitro and in-vivo studies. J Control Release. 2020;326:245-55.
  8. Lu D, Wang H, Feng C, Bai T, Xu B, Wei Y, et al. Spin-coating-based facile annular photodynamic intraocular lens fabrication for efficient and safer posterior capsular opacification prevention. ACS Appl Mater Interfaces. 2022;14(43):48341-55.
  9. Leydolt C, Schartmüller D, Schwarzenbacher L, Röggla V, Schriefl S, Menapace R. Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. Am J Ophthalmol. 2020;217:224-31. 
  10. Darian-Smith E, Safran SG, Coroneo MT. Lens epithelial cell removal in routine phacoemulsification: Is it worth the bother? Am J Ophthalmol. 2022;239:1-10. 
  11. Matossian C. Noncompliance with prescribed eyedrop regimens among patients undergoing cataract surgery—prevalence, consequences, and 
solutions. US Ophthalmic Rev. 2020;13(1):18-22.
  12. Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204-12. 
  13. Larsen J, Whitt T, Parker B, Swan R. A randomized, controlled, prospective study of the effectiveness and safety of an intracanalicular dexamethasone ophthalmic insert (0.4 Mg) for the treatment of post-operative inflammation in patients undergoing refractive lens exchange (RLE). Clin Ophthalmol. 2021;15:2211-7.
  14. Coassin M, Iovieno A, Soldani A, Cavuto S, Cimino L, Sartori A, et al. Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome. J Cataract Refract Surg. 2016;42(8):1119-25.
  15. Group SoUNW. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509-16.
  16. Pranathi K, Magdum RM, Maheshgauri R, Patel K, Patra S. A study of complications during cataract surgery in patients with pseudoexfoliation syndrome. J Clin Ophthalmol Res. 2014;2(1):7.
  17. Nikkhah H, Niazpour Moez R, Entezari M, Ramezani A, Hassanpour K, Karimi S, et al. Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):2949-59.
  18. Hoffman RS, Braga-Mele R, Donaldson K, Emerick G, Henderson B, Kahook M, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2016;42(9):1368-79. 
  19. Seol BR, Shin JY, Choi S, Kang TG, Jeoung JW, Park KH. Intraocular pressure (IOP) change and frequency of IOP spike after cataract surgery in normal-tension glaucoma: A case-control study. J Glaucoma. 2019;28(3):201-6.
  20. Kristianslund O, Østern AE, Råen M, Sandvik GF, Drolsum L. Does cataract surgery reduce the long‐term risk of glaucoma in eyes with pseudoexfoliation syndrome? Acta Ophthalmol. 2016;94(3):261-5.
  21. Vahedian Z, Salmanroghani R, Fakhraie G, Moghimi S, Eslami Y, Zarei R, et al. Pseudoexfoliation syndrome: Effect of phacoemulsification on intraocular pressure and its diurnal variation. J Curr Ophthalmol. 2015;27(1-2):12-5.
  22. Wormstone IM, Wormstone YM, Smith AJO, Eldred JA. Posterior capsule opacification: What's in the bag? Prog Retin Eye Res. 2021;82:100905. 
  23. Hecht I, Karesvuo P, Achiron A, Elbaz U, Laine I, Tuuminen R. Anti-inflammatory medication after cataract surgery and posterior capsular opacification. Am J Ophthalmol. 2020;215:104-11. 
  24. Sufi AR, Mufti AA, Nazir N, Qureshi T, Ramzan R. Prevalence of pseudoexfoliation syndrome in patients scheduled for cataract surgery in eye camps in Kashmir. J Clin Ophthalmol Res. 2014;2(3):137.
  25. Maca SM, Amon M, Findl O, Kahraman G, Barisani-Asenbauer T. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. Am J Ophthalmol. 2010;149(5):777-84.
  26. Sahu S, Ram J, Bansal R, Pandav SS, Gupta A. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on post-operative inflammation using laser flare photometry in patients having phacoemulsification. J Cataract Refract Surg. 2015;41(10):2043-8.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.